U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C68H106N11O15
Molecular Weight 1317.6339
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VEDOTIN FRAGMENT

SMILES

[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN4C(=O)CC([He])C4=O)C(C)C)C=C3)C(C)C

InChI

InChIKey=ERROR

HIDE SMILES / InChI

Molecular Formula C68H106N11O15
Molecular Weight 1317.6339
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 12 / 12
E/Z Centers 0
Optical Activity UNSPECIFIED

Vedotin fragment (Monomethyl auristatin E, MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. MMAE is a potent radiosensitizer. MMAE radiosensitization can be localized to tumors by targeted activatable cell-penetrating peptides.

Approval Year

PubMed

PubMed

TitleDatePubMed
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.
2010 Feb 1
Brentuximab vedotin.
2011
Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.
2015 Apr 1

Sample Use Guides

Vedotin fragment (MMAE) was incubated at 1-1000 nM with cultured primary human hepatocytes for 72 h, and CYP1A2, CYP2B6, and CYP3A4 mRNA expression was assessed by quantitative reverse transcription-polymerase chain reaction and CYP-specific probe substrate by liquid chromatography coupled with mass spectrometry, along with microtubule disruption by immunofluorescence staining using anti-β-tubulin antibody and imaging. MMAE up to 10 nM had no significant effect on CYP1A2, CYP2B6, and CYP3A4 mRNA expression and activity, whereas at higher concentrations of 100- and 1000-nM MMAE, the CYP mRNA expression and activity were diminished substantially. At the clinical dose, the concentration of MMAE was 7 nM which did not show any significant CYP suppression or microtubule disruption in hepatocytes.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:59:17 UTC 2023
Edited
by admin
on Sat Dec 16 13:59:17 UTC 2023
Record UNII
Q3606FDE0B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VEDOTIN FRAGMENT
Common Name English
CONJUGATED FORM OF MC-VC-PAB-MMAE
Common Name English
VEDOTIN [USAN]
Common Name English
VEDOTIN (FRAGMENT)
Common Name English
VEDOTIN RADICAL
Common Name English
PAB-MMAE
Code English
VEDOTIN
USAN  
USAN  
Official Name English
Classification Tree Code System Code
NCI_THESAURUS C67422
Created by admin on Sat Dec 16 13:59:19 UTC 2023 , Edited by admin on Sat Dec 16 13:59:19 UTC 2023
Code System Code Type Description
FDA UNII
Q3606FDE0B
Created by admin on Sat Dec 16 13:59:19 UTC 2023 , Edited by admin on Sat Dec 16 13:59:19 UTC 2023
PRIMARY
NCI_THESAURUS
C152842
Created by admin on Sat Dec 16 13:59:19 UTC 2023 , Edited by admin on Sat Dec 16 13:59:19 UTC 2023
PRIMARY
ChEMBL
CHEMBL2364667
Created by admin on Sat Dec 16 13:59:19 UTC 2023 , Edited by admin on Sat Dec 16 13:59:19 UTC 2023
PRIMARY
SMS_ID
300000044630
Created by admin on Sat Dec 16 13:59:19 UTC 2023 , Edited by admin on Sat Dec 16 13:59:19 UTC 2023
PRIMARY
Related Record Type Details
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
PARENT -> DERIVATIVE
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE -> TOXIN
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT
MOLECULAR FRAGMENT
CONJUGATE -> TOXIN
CONJUGATED ANTIGEN -> CONJUGATE COMPONENT
CONJUGATE -> TOXIN
CONJUGATE->CONJUGATE COMPONENT
CONJUGATE->CONJUGATE COMPONENT